Amgen Middle East Regulatory Director On Regulatory Expertise And Drug Pricing - An Interview With PharmAsia News
This article was originally published in The Pink Sheet Daily
Executive Summary
Against a backdrop of drug price reductions enforced by governments across the region, the pricing issue has become the single largest regulatory challenge facing Dubai-based Amgen Middle East.
You may also be interested in...
Can Emerging Markets Fuel Growth And Restore Trust In Pharma?
When looking at emerging markets, most biopharma analysts focus on commercial opportunities - whether "pharmerging" markets will help mitigate lost sales in the U.S. and Europe stemming from the patent cliff, increasing pressure from payers and related challenges
Egyptian Drug Price Reform: New Trade Barrier Or Demand Driver?
Egypt, an emerging pharmaceutical market, is implementing a series of healthcare and drug pricing reforms. The new drug pricing regime, a streamlined registration process and the government's initiative to widen health insurance coverage, could help drive up domestic demand for pharmaceutical products, especially for branded generics in the country
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.